New Drug Application Submitted for Linhaliq as Treatment of Pseudomonas Aeruginosa Infection in NCFBE Patients
News
The pharmaceutical company Aradigm has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq (ciprofloxacin) as a treatment for non-cystic fibrosis bronchiectasis (NCFBE) in patients with chronic lung ... Read more